Bayer/Regeneron Phase III Will Study Eight-Week Dosing With VEGF Trap-Eye
This article was originally published in The Pink Sheet Daily
Executive Summary
Non-inferiority trial will compare the VEGF Trap-Eye candidate to Genentech’s Lucentis.
You may also be interested in...
Regeneron, Bayer’s VEGF Drug Closing The Gap On Lucentis
Receptor fusion protein’s Phase II data suggest two potential advantages.
Regeneron, Bayer’s VEGF Drug Closing The Gap On Lucentis
Receptor fusion protein’s Phase II data suggest two potential advantages.
Sanofi Strengthens Monoclonal Antibody Access With $560 Million Regeneron Deal
One of the first candidates targeted for development will be an interleukin-6 receptor, a potential competitor to TNF inhibitors, for RA.